Australian biotech company, Alterity Therapeutics Limited, is aiming to combat several neurological disorders - including Alzheimer's, Huntington's, and Parkinson's diseases - by developing therapeutic drugs. The company's lead drug candidate, ATH434, has concluded Phase I clinical trials in the treatment of Parkinson's disease. Additionally, Alterity Therapeutics Limited is working on PBT2, a drug that has completed Phase 2a clinical trials to treat Alzheimer's disease. Formerly known as Prana Biotechnology Limited, the Melbourne-based company rebranded in April 2019. Since its incorporation in 1997, it has focused on the research and development of innovative drugs to address debilitating neurological conditions.
Alterity Therapeutics Limited's ticker is ATHE
The company's shares trade on the NASDAQ stock exchange
They are based in Melbourne, Australia
There are 11-50 employees working at Alterity Therapeutics Limited
It is https://alteritytherapeutics.com/
Alterity Therapeutics Limited is in the Healthcare sector
Alterity Therapeutics Limited is in the Biotechnology industry
The following five companies are Alterity Therapeutics Limited's industry peers: